Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 11/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.42 |
| ▸ | JAK1 | P23458 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24549101 | 1.00 | TLR9 (0.42) | TLR9TLR8TLR7JAK1JAK2 | |
| SCHEMBL24549464 | 0.87 | SYK (0.37) | JAK1JAK2TYK2KCNH2BTK | |
| SCHEMBL29653718 | 0.87 | SYK (0.37) | JAK1JAK2TYK2KCNH2BTK | |
| SCHEMBL24549232 | 0.86 | KCNH2 (0.44) | TLR9TLR8TLR7KCNH2BTK | |
| SCHEMBL24549228 | 0.85 | SYK (0.38) | KCNH2BTKSYK | |
| SCHEMBL29132145 | 0.84 | BTK (0.37) | TLR9TLR8TLR7KCNH2BTK | |
| SCHEMBL24549239 | 0.84 | BTK (0.42) | BTKSYK | |
| SCHEMBL24549233 | 0.83 | SYK (0.35) | KCNH2BTKSYK | |
| SCHEMBL24548986 | 0.82 | SYK (0.37) | JAK1JAK2TYK2JAK3KCNH2 | |
| SCHEMBL24549099 | 0.82 | PRKAB2 (0.43) | TLR9TLR8TLR7JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051970-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-02-15 | — | — | US | disclosed |
| EP-4263531-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022133098-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051970-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | TLR9 26/4885TLR8 58/4885TLR7 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.